{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:47:18Z","timestamp":1792820838353,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.eclinm.2024.102862","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:03:18Z","timestamp":1728043398000},"page":"102862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd J.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"El-Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo","family":"Mirante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.eclinm.2024.102862_bib1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMc1803343","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102862_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102862_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","article-title":"Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer","volume":"68","author":"Fizazi","year":"2015","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102862_bib4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.eclinm.2024.102862_bib5","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/cancers15204907","article-title":"Prognostic value of the De Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [(177)Lu]Lu-PSMA-617 radioligand therapy","volume":"15","author":"Gaal","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102862_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12149-020-01567-3","article-title":"Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with (177)Lu-labeled prostate-specific membrane antigen","volume":"35","author":"Huang","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102862_bib7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s00259-020-05082-5","article-title":"Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer","volume":"48","author":"Rasul","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102862_bib8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pros.24518","article-title":"Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study","volume":"83","author":"Telli","year":"2023","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102862_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102862_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2967\/jnumed.116.178228","article-title":"Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617","volume":"58","author":"Ferdinandus","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102862_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102862_bib12","series-title":"FDA approves Pluvicto for metastatic castration-resistant prostate cancer","year":"2022"},{"key":"10.1016\/j.eclinm.2024.102862_bib13","series-title":"Pluvicto","year":"2022"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102862_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102862_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"supplement","key":"10.1016\/j.eclinm.2024.102862_bib16","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/j.annonc.2020.08.896","article-title":"637P the prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): a post-hoc analysis of the ALSYMPCA phase-III trial","volume":"31","author":"Meisel","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102862_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100241","article-title":"Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study","volume":"6","author":"de Wit","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2024.102862_bib18","series-title":"Biochemistry, lactate dehydrogenase. StatPearls","author":"Farhana","year":"2023"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102862_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12291-013-0408-y","article-title":"Alkaline phosphatase: an overview","volume":"29","author":"Sharma","year":"2014","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.eclinm.2024.102862_bib20","series-title":"StatPearls","article-title":"Neutrophilia","author":"Tahir","year":"2023"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102862_bib21","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/RLU.0000000000004222","article-title":"Outcome of 177 Lu-PSMA radionuclide treatment in advanced prostate cancer and its association with clinical parameters: a single-center experience","volume":"47","author":"Simsek","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102862_bib22","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/pros.24419","article-title":"Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors","volume":"82","author":"Yazgan","year":"2022","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102862_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/biomet\/asq017","article-title":"The horseshoe estimator for sparse signals","volume":"97","author":"Carvalho","year":"2010","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102862_bib24","first-page":"1","article-title":"brms: an R package for bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.eclinm.2024.102862_bib25","author":"Harrell"},{"key":"10.1016\/j.eclinm.2024.102862_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2020.103496","article-title":"A\u00a0practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models","volume":"108","author":"Longato","year":"2020","journal-title":"J\u00a0Biomed Inform"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102862_bib27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.eclinm.2024.102862_bib28","series-title":"survMisc: miscellaneous functions for survival data","author":"Dardis","year":"2013"},{"issue":"10276","key":"10.1016\/j.eclinm.2024.102862_bib29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102862_bib30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2024.102862_bib31","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy","volume":"40","author":"Kuo","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2024.102862_bib32","article-title":"Association of baseline quantitative [68Ga]Ga-PSMA-11 PET imaging parameters with clinical outcomes in patients with mCRPC receiving [177Lu]Lu-PSMA-617: a VISION sub-study","volume":"50","author":"Kuo","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"10.1016\/j.eclinm.2024.102862_bib33","first-page":"1351","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy","volume":"83","author":"Stangl-Kremser","year":"2023","journal-title":"Prostate"},{"issue":"47","key":"10.1016\/j.eclinm.2024.102862_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035843","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617","volume":"102","author":"Sahin","year":"2023","journal-title":"Medicine (Baltim)"},{"issue":"suppl 16","key":"10.1016\/j.eclinm.2024.102862_bib35","article-title":"[177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: prior and concomitant treatment subgroup analyses of the VISION trial","volume":"40","author":"Vaishampayan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102862_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"issue":"61","key":"10.1016\/j.eclinm.2024.102862_bib37","doi-asserted-by":"crossref","first-page":"103108","DOI":"10.18632\/oncotarget.21600","article-title":"Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102862_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.euf.2016.09.008","article-title":"Differences in trial and real-world populations in the Dutch castration-resistant prostate cancer registry","volume":"4","author":"Westgeest","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102862_bib39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102862_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J\u00a0Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T13:19:42Z","timestamp":1737811182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024004413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"alternative-id":["S2589537024004413"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102862","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102862"}}